Bombay HC: FDA Actions Disproportionate, Urges Restraint

What Happened

The Bombay High Court has directed the Maharashtra Food and Drug Administration (FDA) to grant pharmaceutical companies a hearing before initiating action against their products. The court observed that the regulator was employing excessive force, likening their approach to using a "sword to kill a mosquito."

A Division Bench, comprising Acting Chief Justice Ravindra Ghuge and Justice Gautam Ankhad, made these remarks while adjudicating a case filed by Cadila Pharmaceuticals Limited. The company challenged the FDA's decision to halt the sale and distribution of certain medicines and seize stock valued at ₹2.45 crore across Maharashtra due to perceived branding similarities.

Key Facts

• The Bombay High Court directed the Maharashtra FDA to provide hearings before taking action against pharmaceutical companies.
• The court characterized the FDA's actions as using a "sword to kill a mosquito."
• Cadila Pharmaceuticals Limited filed a petition challenging the FDA's order to ban the sale and distribution of its medicines and seize stock worth ₹2.45 crore.
• The FDA's action was reportedly due to branding similarities and was described as a preventive measure by the government pleader.
• The FDA agreed to revoke its orders against Cadila Pharmaceuticals, issue show-cause notices, and grant a hearing before issuing a reasoned order.
• The High Court accepted the government pleader's statement and disposed of the petition.
• The High Court warned of imposing costs on the FDA, noting a pattern of similar actions by the regulator.

Background

The case involved Cadila Pharmaceuticals Limited challenging the FDA's move to stop its products and seize inventory over branding similarities. The government pleader stated that the decision was a preventive measure amid confusion between the medicines.

Why It Matters

The High Court's intervention highlights concerns about regulatory overreach and the need for due process. The court's strong remarks suggest a pattern of disproportionate action by the FDA, emphasizing that regulatory power must be exercised with restraint and proper procedure, even in cases of alleged minor infractions.